Recent Updates
Recently added Catalysts

Bimatoprost 1% Formulation A

Phase 1

Androgenetic Alopecia | Small molecule | Dermatology |AbbVie Inc.|Last Updated: Oct 26, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment11

FDA Designations

No designations recorded

Clinical trial landscape

Bimatoprost 1% Formulation A · 1 trial · 1 indication

Phase 1 1
NCT02848300Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic AlopeciaAndrogenetic Alopecia
COMPLETED11 Analytics
PHASE1COMPLETED
Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia
Androgenetic AlopeciaUnlock trial analytics

Study Endpoints

Primary Endpoints

Drug Concentration in Skin Biopsy Samples
Day 14
Percentage of Participants with at Least 1 Treatment Emergent Adverse Event
28 Days
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
All ParticipantsEXPERIMENTALBimatoprost 1% Formulation A solution applied to the left side of the scalp and trunk area and Bimatoprost 1% Formulation B solution applied to the right side of the scalp and trunk area once daily for 14 days.

Interventions

NameTypeDescription
Bimatoprost 1% Formulation ADRUGBimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
Bimatoprost 1% Formulation BDRUGBimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 49 Years
SexMALE
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: -Patients with mild to moderate Androgenetic Alopecia of the vertex area of the scalp. Exclusion Criteria: * Patients with uncontrolled systemic disease * History of significant cardiovascular disease * Scarring disease, infection, or abnormality of the scalp or hair shaft or ...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Bimatoprost 1% Formulation A

What is Bimatoprost 1% Formulation A used for?

Bimatoprost 1% Formulation A is an investigational small molecule being developed for androgenetic alopecia, a common form of hair loss. It is applied to the scalp and is currently in Phase 1 clinical development.

Who makes Bimatoprost 1% Formulation A?

Bimatoprost 1% Formulation A is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV.

What phase is Bimatoprost 1% Formulation A in?

Bimatoprost 1% Formulation A is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed.

What clinical trials is Bimatoprost 1% Formulation A in?

Bimatoprost 1% Formulation A has one completed Phase 1 trial, NCT02848300, which studied local pharmacokinetics and tolerability of the drug applied to the scalp in male patients with androgenetic alopecia. The trial enrolled 11 participants in the United States.

Is Bimatoprost 1% Formulation A the same as bimatoprost?

Bimatoprost 1% Formulation A is a specific formulation of bimatoprost, a small molecule. It is being studied for androgenetic alopecia, whereas bimatoprost is also known for other uses. The 1% formulation is distinct in its concentration and application.